Articles from Edwards Lifesciences Corporation

Edwards Lifesciences Corporation (NYSEEW) today announced it will participate in the J.P. Morgan Healthcare Conference on Tuesday, Jan. 14, 2025.

Edwards Lifesciences Corporation (NYSEEW) will discuss the company’s focused strategy for long-term sustainable growth, provide an update on its technology pipeline to serve more patients and share financial guidance today during its annual investor conference. Edwards enters 2025, its first full year as a purely structural heart company, in a strong position with major growth drivers in Transcatheter Aortic Valve Replacement (TAVR) and Transcatheter Mitral and Tricuspid Therapies (TMTT), the continued long-term performance of Surgical, and future opportunities with Structural Heart Failure and Aortic Regurgitation (AR).

Edwards Lifesciences (NYSEEW) today announced one-year data highlighting the continued outstanding performance of its SAPIEN 3 Ultra RESILIA valve. The data were presented at PCR London Valves 2024 and simultaneously published in the Journal of the American College of Cardiology (JACC): Cardiovascular Interventions.

Edwards Lifesciences (NYSEEW) today announced significant additions to the body of high-quality evidence presented and published during the Transcatheter Cardiovascular Therapeutics (TCT) conference, addressing the critical needs of patients with structural heart disease.

Edwards Lifesciences Corporation (NYSEEW) today announced that the EVOQUE system demonstrated superiority compared to medical therapy alone for the one-year primary endpoint of the TRISCEND II trial. TRISCEND II is a randomized controlled pivotal trial designed to study the groundbreaking EVOQUE transcatheter tricuspid valve replacement (TTVR) system with optimal medical therapy (OMT) compared to OMT alone with 2:1 randomization. The data, presented during the late-breaking clinical trial sessions at the Transcatheter Cardiovascular Therapeutics (TCT) meeting, included the full cohort of 400 patients. TRISCEND II trial one-year primary endpoint outcomes will be simultaneously published in The New England Journal of Medicine, and TRISCEND II trial one-year quality-of-life (QoL) outcomes will be simultaneously published in the Journal of the American College of Cardiology.

Edwards Lifesciences (NYSEEW) today announced results from the EARLY TAVR Trial, the first randomized, controlled trial designed to study the best strategy for treating asymptomatic severe aortic stenosis (AS) and the benefits of early intervention with transcatheter aortic valve replacement (TAVR). The trial results demonstrated that asymptomatic severe AS patients randomized to Edwards TAVR experienced superior outcomes compared with guideline-recommended clinical surveillance. Trial investigators presented the data today during a late-breaking clinical trials session at Transcatheter Cardiovascular Therapeutics (TCT), the annual scientific symposium of the Cardiovascular Research Foundation (CRF) and published simultaneously in The New England Journal of Medicine.

Edwards Lifesciences (NYSEEW) today reported financial results for the quarter ended Sept. 30, 2024.

Edwards Lifesciences (NYSEEW) plans to announce its operating results for the quarter ended September 30, 2024 after the market closes on Thursday, October 24, 2024, and will host a conference call at 5:30 p.m. ET that day to discuss those results.

Edwards Lifesciences (NYSEEW) has successfully completed the sale of its Critical Care product group to BD (Becton, Dickinson and Company) NYSE: BDXNYSEBDX)

Please replace the release with the following corrected version.

Edwards Lifesciences Corporation (NYSEEW) today announced it will participate in the Wells Fargo Healthcare Conference on Thursday, Sept. 5, 2024.

Edwards Lifesciences (NYSEEW) today announced investments that reflect the company’s deep commitment to advancing patient care through structural heart innovation, addressing large unmet patient needs and supporting sustainable long-term growth.

Edwards Lifesciences (NYSEEW) today reported financial results for the quarter ended June 30, 2024.

Edwards Lifesciences (NYSEEW) plans to announce its operating results for the quarter ended June 30, 2024 after the market closes on Wednesday, July 24, 2024, and will host a conference call at 5:00 p.m. ET that day to discuss those results.

Edwards Lifesciences (NYSEEW) today announced it has exercised its option to acquire Innovalve Bio Medical Ltd., an early-stage transcatheter mitral valve replacement (TMVR) company, following its initial investment in 2017. Since that time, Innovalve has demonstrated progress in its program with promising early clinical experience.

Edwards Lifesciences (NYSEEW) today announced the results from an analysis of data from the PARTNER Trials examining outcomes of transcatheter aortic valve replacement (TAVR) patients with a small annulus. Through five-year follow up of more than 1,300 low and intermediate risk SAPIEN 3 valve patients there were excellent clinical outcomes and valve durability irrespective of the patient’s annulus size or sex. These data were presented during the late-breaking clinical sessions at New York Valves 2024: The Structural Heart Summit.

Edwards Lifesciences (NYSEEW) today announced it has entered into a definitive agreement to sell its Critical Care product group to BD (Becton, Dickinson and Company) NYSE: BDXNYSEBDX)

Edwards Lifesciences (NYSEEW) today reported financial results for the quarter ended March 31, 2024.

Edwards Lifesciences (NYSEEW) plans to announce its operating results for the quarter ended March 31, 2024 after the market closes on Thursday, April 25, 2024, and will host a conference call at 5:00 p.m. ET that day to discuss those results.

Edwards Lifesciences (NYSEEW) announced the release of data from the HUDDLE study that examined the prevalence of heart disease and associated risk factors among members of the National Football League (NFL) Alumni Association and their families. The findings of this study, which identified a significant discrepancy between participant self-awareness and actual prevalence of heart disease and associated risk factors, were presented today during a late-breaking clinical trials session at the American College of Cardiology (ACC.24/WCC) and published simultaneously in The Journal of the American College of Cardiology.

Edwards Lifesciences (NYSEEW) announced today at Cardiovascular Research Technologies (CRT) 2024 the compelling results from two large, real-world studies based on TVT Registry data that demonstrated continued excellent outcomes for patients treated with the Edwards SAPIEN valve platform.

Edwards Lifesciences Corporation (NYSEEW) today announced it will participate in the TD Cowen Healthcare Conference on Tuesday, March 5, 2024.

Edwards Lifesciences (NYSEEW) today reported financial results for the quarter ended December 31, 2023.

Edwards Lifesciences Corporation (NYSEEW) today announced the company’s EVOQUE tricuspid valve replacement system is the first transcatheter therapy to receive U.S. Food and Drug Administration (FDA) approval for the treatment of tricuspid regurgitation (TR). The EVOQUE system is indicated for the improvement of health status in patients with symptomatic severe TR despite optimal medical therapy (OMT), for whom tricuspid valve replacement is deemed appropriate by a heart team.

Edwards Lifesciences (NYSEEW) plans to announce its operating results for the quarter ended December 31, 2023 after the market closes on Tuesday, February 6, 2024, and will host a conference call at 5:00 p.m. ET that day to discuss those results.

Edwards Lifesciences Corporation (NYSEEW) today announced it will participate in the J.P. Morgan Healthcare Conference on Tuesday, Jan. 9, 2024.

Edwards Lifesciences Corporation (NYSEEW) will discuss the company’s sharpened focus and strategy for longer-term growth, provide an update on its technology pipeline and share financial guidance1 today during its annual investor conference.